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Abstract
Background: Using a combined in silico approach, we investigated the glycosylation of T cell
epitopes and autoantigens. The present systems biology analysis was made possible by currently
available databases (representing full proteomes, known human T cell epitopes and autoantigens)
as well as glycosylation prediction tools.
Results: We analyzed the probable glycosylation of human T cell epitope sequences extracted
from the ImmuneEpitope Database. Our analysis suggests that in contrast to full length SwissProt
entries, only a minimal portion of experimentally verified T cell epitopes is potentially N- or O-
glycosylated (2.26% and 1.22%, respectively). Bayesian analysis of entries extracted from the
Autoantigen Database suggests a correlation between N-glycosylation and autoantigenicity. The
analysis of random generated sequences shows that glycosylation probability is also affected by
peptide length. Our data suggest that the lack of peptide glycosylation, a feature that probably
favors effective recognition by T cells, might have resulted in a selective advantage for short
peptides to become T cell epitopes. The length of T cell epitopes is at the intersection of curves
determining specificity and glycosylation probability. Thus, the range of length of naturally occurring
T cell epitopes may ensure the maximum specificity with the minimal glycosylation probability.
Conclusion: The findings of this bioinformatical approach shed light on fundamental factors that
might have shaped adaptive immunity during evolution. Our data suggest that amino acid sequence-
based hypo/non-glycosylation of certain segments of proteins might be substantial for determining
T cell immunity/autoimmunity.
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Background
Antigen recognition by the immune system is decisive in
the fight against pathogens and tumors. T lymphocytes
recognize short, linear peptide fragments (epitopes) of
antigenic proteins in context with self MHC.
Posttranslational protein modifications (PTMs) generate
an enormous variety of modified protein-derived
epitopes. However, the significance of the posttranslation-
ally modified antigenic determinants in shaping the
receptor repertoire and determining the outcome of an
immune response, is poorly understood. Within the cate-
gory of PTMs, glycosylation is the most frequent one, and
N-glycosylation is the most abundant form of glycosyla-
tion in humans. The relative backlog in the understanding
of glycoimmunology (as compared to anti-protein immu-
nology) might be explained, at least partially, by the sub-
stantial technical difficulties of carbohydrate synthesis
and sequencing. Fortunately, in the past years there has
been an explosion of progress in glycobiology and also in
glycoimmunology. However, despite the extensive work,
fundamental questions (such as the role of epitope glyco-
sylation in T cell recognition) remain to be answered.
Glycosylation of a peptide increases its space-filling capac-
ity, thus, altering its interactive surface with the TCR or
with MHC. While it is obvious that glycosylation creates
new ligands for different B cell receptors, it is yet unclear
how it affects epitope recognition by T cells. The aim of
this study was to investigate the impact of glycosylation
on T cell recognition. According to our hypothesis, glyco-
sylated peptides are less likely to be recognized by T cells
because of the glycan moiety. Indeed, there are sporadic
experimental data suggesting that peptide glycosylation
may interfere with epitope recognition through TCR [1-3].
On the other hand, alterations in protein glycosylation
may also play a role also in the pathogenesis of autoim-
mune diseases. The molecular mimicry theory predicts
that a cross-reactive immune response to similar or iden-
tical antigen determinants of microbial and human ori-
gin, may result in a pathological immune response
directed against self antigens. In line with this concept,
self-nonself discrimination of exact sequence matches is
possible as long as the peptides are differentially glyco-
sylated. Removal of the glycan moiety in pathological
conditions might, however, result in a facilitated recogni-
tion of a formerly tolerated epitope. In order to test this
possibility, we compared the glycosylation frequency of
the complete human proteome with that of the experi-
mentally verified T cell epitopes and the bacterial proteins
with mimicry potential.
The relevance of epitope glycosylation in the development
of autoimmunity has been recently suggested by the find-
ing that an increased substrate flux through N-glycosyla-
tion machinery has a therapeutic effect in some
autoimmune diseases [4].
Publicly available T cell epitope prediction approaches
focus on binding of a given peptide to HLA and not to
TCR. Furthermore, it has also been described recently that
the currently available in silico tools are rather limited in
their prediction efficiency, which also differs from allele
to allele [5]. This study was motivated by the urge to
explore further antigenicity-related characteristics of pep-
tides in order to improve the accuracy of T cell epitope
prediction. In order to study the role of epitope glycosyla-
tion on T cell immunity, we used combined state of the art
bioinformatics tools (databases and neural network-
based glycosylation prediction algorithms).
Materials and methods
Protein and peptide datasets
Protein sequences analyzed in the study derive from the
taxonomic divisions provided by the UniProt Knowledge-
Base [6,7]. These data sets contain all entries of Uni-
ProtKB/SwissProt database corresponding to a given
taxonomic group. In the current study, 16 440 human and
140 337 bacterial entries of the database's taxonomic divi-
sions, all protein sequences available on Aug 22/2007,
were used. These sequences were used for prediction of
glycosylation and MHC-binding sites, while annotation
in the FT (function) line was applied to verify prediction
results and also was used for Bayesian statistics. Data con-
version from the FASTA format into our database was
manually revised, and in very few cases, truncated
sequences and annotations to non-appropriate category
columns were corrected according to re-retrieved data
from SwissProt database.
Experimentally verified human protein-derived T cell
epitopes (1782 different entries) were downloaded from
IEDB v 1.0 [8,9]. First a transitional database was gener-
ated by performing an advanced query for positive T cell
response to "structure/chemical type: peptide/protein"
and "source species: homo sapiens". The output did not
provide any data concerning the MHC I or MHC II restric-
tion of T cell recognition of the given epitope. Given the
known length range of MHC I and MHC II binding
epitope sequences [10], we considered ≤ 10 and ≥ 13 aa
long peptides as MHC I-restricted and MHC II-restricted T
cell epitopes, respectively. Any redundancy in the data-
base was eliminated based on the information provided
on the source protein of the epitope. The corresponding
SwissProt entry was looked up for each source, and amino
acid positions within the full length proteins were
assessed. A small proportion of retrieved entries that
could not be matched with any human SwissProt protein,
were excluded from further analysis. Only the unique
"epitope sequence-protein of origin-amino acid position"Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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data were used for further analysis. Protein sequences of
known autoantigens are listed in the Autoantigen Data-
base [11,12]; we used the whole database, instead of que-
rying particular diseases. Both the sequence and SwissProt
ID found here were used to determine autoantigenic (n =
440) and non-autoantigenic (n = 16 000) proteins.
Predictions
Glycosylation of proteins was assessed by the prediction
servers of the Center for Biological Sequence Analysis [13]
using the NetOglyc (sensitivity: 76%; specificity 93%)
[14,15] and NetNGlyc (sensitivity: 86%; specificity: 61%)
[16] servers, trained on a relative large set of experimental
data. Other glycosylation prediction methods have been
also described [17-21]. From among the currently availa-
ble glycosylation-related bioinformatics tools summa-
rized recently by Petrescu et al. [22], we used the in silico
predictions of glycosylation.
N-glycosylation of proteins occurs at a well defined
sequence motif (NXS/T), where X can be any amino acid
other than proline. This motif is referred to as "condi-
tional" N-glycosylation site throughout the study.
Depending on the second amino acid of the triplet, the
probability of glycosylation may vary. This probability
can be assessed by the prediction servers. N-glycosylation
sites predicted as "likely to be glycosylated", are referred to
as "probable N-glycosylation sites" in the text.
As N- and O-glycosylation occur in the ER and Golgi, only
proteins with a signal peptide (SigP) are expected to be
glycosylated. Glycosylation of proteins by other mecha-
nisms (e.g. by Yin-Yang glycosylation) has not been stud-
ied here. Besides prediction of SigPs, prediction of the
transmembrane regions of proteins was also carried out
by servers provided at the CBS homepage [23-27]. The lat-
ter predictions were also important because only extracel-
lular domains of proteins are expected to be N-
glycosylated. Thus, cytoplasmic and transmembrane
sequence regions, predicted to be glycosylated, were
ignored. SigPs were predicted by two methods (Artificial
Neural Networks and Hidden Markov Model), and in
those few cases, in which the results were contradictory,
the annotation of SwissProt was accepted. If no annota-
tion suggested the presence of either a SigP or the localiza-
tion in the ER or Golgi, the protein was considered as one
without a SigP. Another CBS prediction server, NetMHCII
[28,29] was used to assess potential MHC II ligands for
the most common HLA DR alleles [30]. This software was
trained on experimental MHC binding assay data in the
IEDB and the AntiJen database. The AUC values represent-
ing the predictive performance of the method vary
between 0.664 and 0.818, depending on the different alle-
les as described earlier [28]. The prediction yielded an
MHC-binding score for each possible 15 amino acid long
peptide derived from that protein, and for the sequence of
the 9 core amino acids. Both scores were used in our anal-
ysis.
Python Programming Language (Large scale data 
handling)
In this study, we used Python Programming Language
[31]. This script language is becoming increasingly popu-
lar in biological research since the availability of BioPy-
thon toolkit [32]. It was used for submission of sequences
for prediction, for analysis of prediction results, for com-
parison of sequences and for handling data throughout
the study.
The script language was used to detect matching
sequences between human and bacterial proteins. It was
carried out by searching for ≥ 7 aa long sequence frag-
ments of human proteins in the sequences of bacterial
proteins. Python was also used for random selection of
4000 bacterial proteins in order to estimate the correla-
tion between peptide lengths and the number of bacterial-
human sequence matches of 4-6 aa length.
Another application of the programming language was to
generate amino acid composition-matched random con-
trol sequences or to select length-matched peptides from
SwissProt protein sequences. Python uses the Mersenne
Twister algorithm; a pseudo-random number generator
widely used in stochastic applications, like in Monte Carlo
simulation [33].
Random control sequences for autoantigens were gener-
ated by random sampling of amino acids, giving the same
weight to each amino acid as its frequency in the original
protein. For random generated T cell epitope sequences,
the amino acid weight was determined by assessing the
amino acid frequencies among all human proteins with a
signal peptide. The weights were as follows: A: 0.070; C:
0.025; D: 0.048; E: 0.067; F: 0.039; G: 0.069; H: 0.026; I:
0.043; K: 0.055; L: 0.099; M: 0.022; N: 0.036; P: 0.063; Q:
0.046; R: 0.057; S: 0.081; T: 0.053; V: 0.062; W: 0.013; Y:
0.029.
Statistics
Analysis of data was carried out by classical statistical tests
(Statistica software package). We also performed a Baye-
sian analysis of multivariate relevance and interactions
using Bayesian networks [34-37]. The discretization of the
continuous variables was determined by a priori biologi-
cal expertise and univariate statistical analysis. Discretiza-
tion criteria were as follows: sequence length: length (0-
500), length (500-100), length (1000<); sequence type
(autoantigen or not): seq_type_id (0), seq_type_id (1);
presence of signal peptide: signalp (0), signalp (1); pres-
ence of Ca binding domain: ca_bind (0), ca_bind (0<);
presence of coiled regions: coiled (0), coiled (0<); pres-
ence of DNA binding motif: dna_bind (0), dna_bindImmunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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(0<); presence of helical structure: helix (0<), helix (0);
presence of metal binding region: metal (0), metal (0<);
nucleoprotein binding: np_bind (0), np_bind (0<); pres-
ence of strands: strand (0), strand (1-10), strand (10<);
presence of turns: turn (0), turn (0<); presence of zinc fin-
ger motif: zn_fing (0), zn_fing (0<); presence of O-glyco-
sylation site between two disulphide bonds: o_disulphide
(0), o_disulphide (1), o_disulphide (1<); O-glycosylation
site coinciding with a repeat sequence: o_repeat (0),
o_repeat (1-10), o_repeat (10<); predicted intracellular
O-glycosylation site: o_IC (0), o_IC (1-10), o_IC (10<);
extracellular O-glycosylation site: o_EC (0), o_EC (1-10),
o_EC (10<); O- glycosylation site within mitochondrial
proteins: o_mitochondrial (0), o_mitochondrial (0<); O-
glycosylation site within a transmembrane domain:
o_transmembr (0), o_transmembr (1); N-glycosylation
site between two disulphide bonds: n_disulphide (0),
n_disulphide (1), n_disulphide (1<); N-glycosylation site
coinciding with a repeat sequence n_repeat (0), n_repeat
(1), n_repeat (2), n_repeat (3); predicted intracellular N-
glycosylation site: n_IC (0), n_IC (1), n_IC (2); extracellu-
lar O-glycosylation site: n_EC (0), n_EC (1), n_EC (1<),
N-glycosylation site within mitochondrial proteins:
n_mitochondrial (0), n_mitochondrial (0<); N-glycosyla-
tion site within a transmembrane domain: n_transmembr
(0), n_transmembr (0<); number of disulphide bridges:
sum_disulphide (0), sum_disulphide (1-10),
sum_disulphide (10<); number of repeats: sum_repeat
(0), sum_repeat (1-10), sum_repeat (10<); number of a
transmembrane domains: sum_transmembr (0),
sum_transmembr (1-4), sum_transmembr (4<); distance
of N-glycosylation sites: n_distance (<0.65), n_distance
(0.65-0.85), n_distance (0.85<); distance of O-glycosyla-
tion sites: o_distance (<0.35), o_distance (0.35-0.8),
o_distance (0.8<); number of N-glycosylation sites:
num_nglyc (0), num_nglyc (1), num_nglyc (2),
num_nglyc (3-4), num_nglyc (5<); number of N-glyco-
sylation sites with more than 75% probability of N-glyco-
sylation site occupancy: num_nglyc3 (0), num_nglyc3 (1-
2), num_nglyc3 (2<); number of O-glycosylation sites:
num_oglyc (0), num_oglyc (1-10), num_oglyc (10<). The
length of the burn-in was selected using Geweke's z-score
test and the R value of the multiple-chain method of Gel-
man-Rubin [35,37]. The length of the MCMC simulation
was selected to decrease the variances of the MCMC esti-
mates below 0.01.
Results
Glycosylation of the human proteome
In order to generate a basis for comparison with antigens
and antigen-derived T cell epitopes, we set to assess the
glycosylation of the human proteome based on sequence
analysis of entries extracted from SwissProt/UniProtKB.
To determine if amino acids that are implicated in glyco-
sylation (e.g. Asn, Ser, Thr), are differentially represented
among the 20 amino acids in the human proteome, we
analyzed 16 440 human protein sequences. We found
that serine represented 8.07% of all amino acids in
humans, while threonine was found at 5.27% and aspar-
agine at 3.6% frequency.
Since glycosylation is expected to imply to SigP-contain-
ing proteins only, we identified SigP-containing
sequences in t SwissProt/UniProtKB database. This filter-
ing yielded in 24.92% of all human proteins. No signifi-
cant difference was identified in the amino acid
composition of proteins with a SigP (7.74% serine, 5.72%
threonine and 3.85% asparagine) in comparison with the
whole proteome.
The next important step was to compare the length of the
members of the proteome with that of the SigP-bearing
proteins. The protein length of the human proteome was
543 amino acids ± 4 (mean ± standard error). Proteins
with a SigP did not differ significantly from this; they were
characterized by a length of 522 ± 8 amino acids (mean ±
standard error).
We next focused on the potential glycosylation of proteins
with and without SigP. We found that 73.54% of the SigP
peptide-bearing sequences were predicted to carry N-glyc-
osylation, while approximately 55.43% of these proteins
were predicted to be O-glycosylated. Considering SigP as
a prerequisite for both N- and O-glycosylations, only
18.31% of the whole human proteome was found to be
N-glycosylated and 13.82% O-glycosylated.
We also compared the distribution of glycosylation sites
along the proteins. As expected, the pattern of N- and O-
glycosylation of proteins showed a marked difference:
while N-glycosylation sites were relatively distant from
one another, O-glycosylation occurred in clusters (Figures
1A and 1B).
Glycosylation of human T cell epitopes
To analyze the probable glycosylation of T cell epitopes,
we extracted all linear human protein-derived T cell
epitope sequences from the ImmuneEpitope Database
(IEDB). In this first analysis, we did not investigate MHC
I and MHC II-related epitopes separately, since the basic
principles of the trimolecular complex formation by a
TCR and a peptide in context with self MHC, are highly
similar. Since the amino acid environment of a possible
glycosylation site also carries important information for
the prediction algorithm to assess the probability of glyc-
osylation, predictions were not carried out directly on the
experimentally verified T cell epitope peptide sequences.
Instead, the glycosylation was predicted for the full lengthImmunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
Page 5 of 12
(page number not for citation purposes)
protein from which the given T cell epitope was derived,
and the information for the T cell epitope sequences,
found in the IEDB, was deduced from these data.
We found that only a very small portion of all experimen-
tally verified human T cell epitopes were potentially N- or
O-glycosylated. Only 2.26% of all T cell epitopes were pre-
dicted to be N-glycosylated, and 1.22% were predicted to
be O-glycosylated. When considering the SigP-bearing
protein-derived epitopes only, 5.68% of the experimen-
tally verified T cell epitopes, and from among them 5.56%
of MHC II-restricted epitopes were N-glycosylated, while
O-glycosylation characterized 3.06% and 3.61% of the
sequences, respectively. We could not identify any amino
acid position N- or C-terminally from the experimentally
verified T cell epitopes that was more prone to either N- or
O-glycosylation.
Although it may seem trivial that longer sequences are
more likely to contain more glycosylation motifs, any evo-
lutionary pressure affecting the glycosylation of epitopes
could significantly bias this correlation. To test this possi-
bility, we generated randomly 100 different n, 5n and 25n
long sequences (where n is the number of amino acids of
the original epitope) as controls for each verified T cell
epitope in the IEDB. We found that 22.07% of the 5n, and
70.54% of the 25n long sequences contained the NXS/T
sequence (not shown). This 70.54% is very close to the
portion found in SwissProt human entries. By generating
10000 random sequences for each peptide length from 7-
30 amino acids, a linear correlation could be found
between the peptide length and the presence of NXS/T
motif as a possible N-glycosylation site (r = 0.99).
As an alternative approach, we also analyzed the probabil-
ity of glycosylation as a function of length, and received
concordant results (data not shown). Thus, the reduced
glycosylation rate of T cell epitopes could theoretically
result from the shortness of these sequences in compari-
son with full-length proteins.
To test if sequence length was the only factor effecting gly-
cosylation, matched random control sequences were also
tested. As a first approach, we randomly generated pools
of 100 different, composition-matched amino acid
sequences of the same length for each T cell epitope in the
IEDB. Only 4.18% of all randomly generated sequences
and 7.73% of randomly generated controls for MHC II
restricted epitopes contained the NXS/T N-glycosylation
motif, which did not differ significantly from the rates
found analyzing all T cell epitopes (3.9%) or MHC II-
restricted epitope sequences (4.72%) (chi square, p =
0.21).
As another approach of control group design, for each
experimentally verified T cell epitope, we randomly
selected a peptide control of identical length from the very
same protein antigen. The experimentally verified
epitopes (n = 1722) and the randomly chosen matched
sequences derived from the same antigen as the T cell
epitope (n = 1722), were compared for the presence of the
NXS/T motif. From among all verified T cell epitopes, 75
contained the NXS/T motif, while it was present in 115 of
the randomly selected matched sequences. To test its sig-
nificance, we used the Wilcoxon signed-rank test in which
each control peptide was paired with an epitope derived
from the same protein (p = 0.005). Probably due to the
smaller sample size, the difference was significant only
when MHC II-restricted T cell epitopes were considered
(Wilcoxon p = 0.056). After testing the presence of the
NXS/T, we also used neural network-based glycosylation
predictions to compare the number of probable N-glyco-
sylation sites for each experimentally verified T cell
epitope and a randomly selected peptide pair of it with
identical length from the same protein. We found that
1.437 times more randomly picked sequences of the same
protein origin were predicted to carry N-glycosylation in
comparison with the functional T cell epitopes (Figure 2,
Wilcoxon p = 0.00006). No significant difference was
found, however, when we compared MHC I- or II-
restricted peptides with the corresponding random con-
trols (1.333 and 1.519 times more sequences were pre-
dicted to be N-glycosylated than the controls,
respectively). This could have, again, resulted from the
smaller sample sizes.
Average distances of glycosylation sites Figure 1
Average distances of glycosylation sites. The histogram 
shows frequency distribution of distances between glycosyla-
tion sites. It shows a markedly different pattern of N- and O-
glycosylation. Most probable O-glycosylation sites are found 
less than 10 amino acids far from each other. In contrast, dis-
tances between probable N-glycosylation sites are highly var-
iable. This indicates that O-glycosylation sites are found in 
clusters, while conditional N-glycosylation sites are more 
equally distributed throughout a protein sequence.Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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As there is no consensus sequence motif of O-glycosyla-
tion sites (Ser and Thr being highly abundant in proteins),
only a prediction algorithm was used to assess the proba-
ble O-glycosylation. Experimentally verified T cell
epitopes were not significantly different from randomly
picked controls regarding their O-glycosylation, except for
MHC I-restricted epitopes, in which the number of O-gly-
cosylation sites was only 42.1% of the randomly picked
control pairs (Wilcoxon p = 0.0257).
Predicted MHC II-binding peptides
Since most SigP-possessing human proteins fall into the
category of either secreted or plasma membrane mole-
cules, they are likely to be presented by MHC II molecules
(similarly to bacterial proteins). To determine peptide
sequences with high probability to bind to some of the
most common human MHC II alleles, we analyzed all
human proteins possessing SigP. Using the most sensitive
prediction method available [28], we studied the MHC II
binding of N- and O-glycosylated peptides.
HLA alleles showed significant differences in the numbers
of predicted strong and weak binder peptides derived
from SigP-containing human proteins. The software uses
binding scores 50 and 500 as threshold values for strong
or weak peptide binding, respectively. However, a recent
study shows that its performance can be enhanced by
shifting these values to 400 and 4000 [38]. Similarly to
what has been seen at 50 and 500 scores, at 400 and 4000
threshold values we could observe differential peptide
binding by different HLA alleles (Figure 3A). HLA DRB1*
0101 showed the most promiscuous peptide binding (Fig-
ure 3A), while HLA alleles HLA DRB1*0301, DRB1*0802
and DRB3*0101 were predicted to bind a significantly
reduced proportion of all human peptides derived from
proteins with SigP (Figure 3A). Similarly, HLA
DQA1*0501 - DQB1*0301 showed significantly higher
promiscuity as compared to other HLA DQ alleles. This
differential permissivity to bind peptide ligands did not
show a correlation with the published area under the
curve (AUC) values that reflect the predictive perform-
ances of the software for the individual MHC alleles [28].
The probability of N- and O-glycosylation Figure 2
The probability of N- and O-glycosylation. Experimen-
tally verified T cell epitopes (filled columns) (found in 
ImmuneEpitope Database) and randomly selected peptides 
with identical length from the same protein (gray columns) 
were analyzed for probable N- and O-glycosylation using 
Artificial Neural Network-based predictions. Probable glyco-
sylation of ≥ 9 amino acid long peptides is shown in the fig-
ure. A peptide was considered to have probable glycosylation 
if the position of the predicted glycosylation site within the 
protein coincided with the position of the peptide. Figure 2A 
shows comparison of the numbers of predicted O-glycosyla-
tion sites for each experimentally verified T cell epitope and 
a randomly selected peptide with identical length from the 
same protein (Wilcoxon, p = 0.0019). Figure 2B shows com-
parison of predicted N-glycosylation of randomly selected, 
length-matched sequences and the functional T cell epitopes 
(Wilcoxon test, p = 0.00006).
Effect of glycosylation on MHC binding Figure 3
Effect of glycosylation on MHC binding. Binding of pep-
tides derived from SwissProt/UniProtKB entries with SigP to 
the most common human HLA II alleles was predicted by 
NetMHCII software. A. HLA alleles showed significant differ-
ences in the numbers of predicted binding peptides. B. Pro-
portion of peptides predicted to carry an N-glycosylation site 
is very different among different MHC II molecules. Most 
HLA DR alleles are found to be more prone tolerate N-glyc-
osylation, than HLA DP and DQ. C. The frequency of proba-
ble O-glycosylation among peptides binding to different HLA 
alleles is shown on a polar graph.Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
Page 7 of 12
(page number not for citation purposes)
To further address the question of MHC II binding, we
next examined the glycosylation of peptides predicted to
bind to the MHC II alleles, mainly HLA DR1 (eg. HLA
DRB1*0401 and HLA DRB1* 1302). Most HLA DP and
DQ alleles seem to tolerate N-glycosylation much less
(Figure 3B) than HLA DR, with the exception of
DQA1*0501 - DQB1*0301. This is also the most promis-
cuous of all HLA DQ. The same allele is found to bind a
very high proportion of O-glycosylated peptides as com-
pared to other HLA alleles (Figure 3C). While HLA DP
alleles bind peptides with only a low portion of O-glyco-
sylation, some of the HLA DR alleles (eg. DRB1*0401,
DRB1*0701, or DRB1*0901) show mild tolerance to this
posttranslational modification (Figure 3C). It is also of
note that three out of the four HLA DQ alleles examined,
seem to tolerate O-glycosylation somewhat more.
Autoantigens
Autopathogenic T cells have been shown to play key roles
in several autoimmune diseases such as multiple sclerosis,
rheumatoid arthritis [39]. As the presence or absence of
glycosylation is possibly associated with the efficacy of T
cell recognition, it might also be involved in determining
autoantigenic nature of a protein. To address this ques-
tion, next we investigated entries in the Autoantigen Data-
base [12]. According to our data autoantigens did not
differ significantly in their amino acid composition from
other components of the proteome. The same proportion
of known autoantigens was identified to have a SigP
(27.61%) as proteins of the human proteome.
The mean length of autoantigens was also similar to that
of normal proteins (510 ± 23), although autoantigens
with a SigP were found to be significantly longer (714 ± 51
amino acids) than the same type SwissProt entries (p <
0.001, Kolmogorov Smirnov test).
In this analysis, a protein was considered to be glyco-
sylated if the glycosylation prediction suggested at least
one probable glycosylation site within the molecule. A
significantly higher proportion of autoantigens proved to
be N-glycosylated (84.48%) than what was found when
analyzing the members in the human proteome (73.54%)
(p < 0.05, Kolmogorov Smirnov test). In contrast, no sig-
nificant difference was observed between frequencies of
O-glycosylation (61.2% as compared to 55.43%).
To test if the observed difference in N-glycosylation of
autoantigens was only due to the different protein length,
we also assessed the glycosylation of length-matched ran-
domly generated sequences as controls (n = 20 000).
Autoantigens were found to contain significantly more N-
glycosylation sites (+1.74 ± 0.32) than normal proteins
(+0.91 ± 0.04) when both data sets were compared to ran-
domly generated control sequences (Figure 4) (Kol-
mogorov Smirnov test, p < 0.001).
The mean number of probable glycosylation sites/protein
was 2.48 ± 0.04 in the case of SigP- bearing non-autoanti-
genic SwissProt/UniProtKB entries, while it was 3.91 ±
0.35 among the autoantigenic sequences (mean ± stand-
ard error mean).
In order to confirm the above data, we also performed a
Bayesian model-based analysis [37]. We calculated the
posterior probability for each variable that it is directly
dependent of a fixed target (outcome) variable Autoanti-
gen (i.e., its probabilistic dependence is not mediated by
other variables). This is formalized as being in the so
called Markov Blanket Set of the variable Autoantigen,
which is denoted with MBM (Autoantigen, Xi) (for an
overview of this symmetric relation, see references in
[36]). The posteriors are listed in Table 1 (variables with
posteriors below 0.001 are not shown). This confirms that
the length, number of N-glycosylation sites, number of
disulfide bonds, number of transmembrane domains,
number of strand domains are relevant variables to
autoantigenicity.
Human-bacterial sequence matches
We analyzed 140000 bacterial SwissProt/UniProtKB
entries found in the corresponding taxonomic division of
the database to identify linear 100% sequence matches
with the human proteome. The minimal peptide length
Number of N-glycosylation sites in autoantigens and non- autoantigenic proteins Figure 4
Number of N-glycosylation sites in autoantigens and 
non-autoantigenic proteins. Human SwissProt/Uni-
ProtKB proteins and known autoantigens (Autoantigen Data-
base) with SigP were examined for the number of probable 
N-glycosylation sites. For each protein, random control 
sequences (n = 5) were generated consisting of the same 
amino acids and of the same length. The mean number of gly-
cosylation sites found in random control sequences was sub-
tracted from the number found in the given protein. The 
frequency of the difference values is shown for both the 
autoantigenic and the non-autoantigenic proteins.Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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was selected according to experimental data suggesting
that most T cell epitopes are in the range of 8-22 amino
acids. A short Python program was used for this function.
The number of continuous linear exact sequence matches
between the whole bacterial and human proteome
decreases logarithmically as the minimal length of the
match is set higher (Figure 5). So does the number of pro-
teins containing bacterial-human exact sequence matches.
In the length range of immunologically relevant peptides
(from the minimum of 8-9 aa for T cell epitopes), exact
sequence matches between human and bacterial proteins
are found in the order of 105, which value is relatively low
when compared to the order of magnitude of TCR diver-
sity. Posttranslational protein modifications such as glyc-
osylation may further decrease the probability of cross-
reactive T cell epitope recognition.
Glycosylation of at least 9 aa long matches were examined
the same way as the glycosylation of T cell epitopes. A lin-
ear matched sequence was considered glycosylated, if its
amino acid position in the protein coincided with a prob-
able glycosylation site. Glycosylated sequence matches
were found to be slightly less N-glycosylated (4.05%)
than O-glycosylated (5.39%) (Figure 2, grey columns).
This difference was higher if only autoantigens were
examined. Human-bacterial sequence matches derived
from these proteins were predicted to be significantly (p <
0.001) less N-glycosylated (3.45%) than O-glycosylated
(6.89%). In contrast to the human-bacterial sequence
matches, the N- and O-glycosylation of autoantigen and
non-autoantigen protein-derived sequence matches did
not differ significantly.
A larger proportion of known autoantigens (56.04%)
contained at least 9 aa long human-bacterial matches
compared to non-autoantigenic human SwissProt/Uni-
ProtKB entries (40.40%) (Figure 6, p < 0.05, Kolmogorov
Smirnov test).
Table 1: Correlation of structural features of proteins with their autoantigenic character
Investigated parameter P (MBM (Autoantigen, Xi)|DN) Kolmogorov-Smirnoff hypothesis test
Length 1 p < 0,001
EC N-glycosylation 1 p < 0,001
Total N-glycosylation 1 p < 0,001
Number of strand motifs 0.986774 p < 0,01
Number of transmembrane regions 1 p < 0,05
Number of turn motifs 0.005305 p < 0,05
Number of disulfide bridges 1 NS
Metal cofactor binding 0.097063 NS
Number of coiled coils 0.094628 NS
Number of alpha helices 0.014117 NS
Extracellular O-glycosylation 0.741702 NS
The presence of SigP 0.377562 NS
Intracellular N-glycosylation 0.132067 NS
Results of a Bayesian model-based analysis.
We calculated the posterior probability for each variable that it is directly dependent of the fixed variable, autoantigenicity of a protein (i.e., its 
probabilistic dependence is not mediated by other variables). This is formalized as being in the so called Markov Blanket Set of the variable 
Autoantigen, which is denoted with MBM (Autoantigen, Xi). Variables relevant to the autoantigen nature of proteins are listed in the table 
(posteriors below 0.001).
Number of bacterial-human exact sequence matches Figure 5
Number of bacterial-human exact sequence 
matches. Human SwissProt/UniProtKB proteins and known 
autoantigens (Autoantigen Database) containing SigP were 
scanned for short exact sequence matches with bacterial 
SwissProt/UniProtKB proteins. The number of these exact 
sequence matches exponentially decreases as their length 
grows. Black dots represent data obtained from the analysis 
of 140 337 bacterial proteins, while empty circles represent 
estimations based on analysis of 4000 randomly selected bac-
terial proteins. Data indicate that from ≥ 9 amino acid pep-
tide lengths the number of bacterial-human sequence 
matches falls below 105.Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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To confirm that the reduced glycosylation of bacterial-
human sequence matches was not due to the short length
of the corresponding peptides, we tested the glycosylation
probabilities along the full length of proteins carrying
sequence matches. The mean probability of N-glycosyla-
tion in the region of sequence matches was below the
50% "threshold" of the prediction (43.92%).
On the contrary, when O-glycosylation probability was
tested, the matching sequences of bacterial-human pro-
teins had glycosylation probability above the threshold
value (56.80%). Both N- and C-terminally to the matched
sequences, the mean O-glycosylation probability was
above the glycosylation threshold (50%), while the mean
probability varied in regions farther from the exact
sequence match.
Discussion
Several autoimmune disease models have been shown to
be dependent on posttranslational modifications of rele-
vant Ags (e.g. on acetylation of a myelin basic protein pep-
tide (MBP-Ac1-11) [40] or on the isoaspartyl-
modification of a self Ag in a mouse model of systemic
lupus erythematosus [41] or of peptides in DR4-trans-
genic mice expressing human type II collagen [42].
Surprisingly, the role of the most common PTM, glyco-
sylation, is poorly understood not only in the develop-
ment of autoimmune diseases, but also in basic immune
processes like T cell recognition.
Instead of using glycosylation-related annotations of
SwissProt/UniProtKB or one of the PTM- specific data-
bases (dbPTM or O-GLCBASE 6.0 [43,44]), in our work,
we chose to use Artificial Neural Network-based glycosyla-
tion prediction tools. By this approach, we could avoid
errors of comparison resulting from publication bias, the
lack of negative results and the diverse methods used to
characterize glycosylation of molecules. Beside the
numerous advantages, the authors are also aware of disad-
vantages of in silico technologies. Prediction methods use
mainly stochastic algorithms, and a known portion of all
provided answers is incorrect. This error, however, can be
taken into account precisely, and be corrected during sta-
tistical analysis, while it is very hard to assess the systemic
bias caused by errors in database entries.
In our study, we compared the glycosylation of experi-
mentally verified T cell epitopes of the IEDB to that of the
human proteome. According to our present knowledge,
the most common types of glycosylation, N- and O-glyc-
osylation, occur only in the rER. Nevertheless, earlier stud-
ies on glycosylation of the proteome have not yet
considered the presence or absence of a (SigP) [45]. Our
data are in accordance with the results of former studies
regarding the frequency of glycosylation. Earlier, based on
the analysis of a smaller pool of 6000 human proteins, it
has been demonstrated that N-glycosylation preferentially
occurs on proteins associated with transport and binding
functions [45]. In another article, the clustering phenom-
enon of O-glycosylation was also reported for 221 glyco-
proteins [15]. Furthermore, N-glycosylation was reported
to occur preferentially in the central and N-terminal
regions of proteins, whereas O-glycosylation showed pref-
erence for both the N- and C-termini [46].
In this study, we found very low glycosylation of the
experimentally verified T cell epitopes in comparison with
the glycosylation of the entire human proteome. This is
logical given the necessity of a TCR to interact simultane-
ously with the alpha helices of the MHC molecule and the
presented peptide. If this peptide is glycosylated, the tri-
molecular complex formation might be prevented
because of steric reasons. Such interference of epitope gly-
cosylation with TCR binding has been indeed, reported
already [1-3]. However, on the other hand, there are also
data on recognition of glycopeptide epitopes by T cells
[2,47-51].
Epitope glycosylation may not only interfere with TCR
binding but also with binding of a peptide to MHC. Many
of the T cell epitopes in the IEDB may represent immuno-
dominant epitopes, those few peptides that are found in
the majority of peptide-MHC complexes during an
immune response after natural intracellular processing of
an Ag [52,53]. Whether glycopeptides suffer any disadvan-
Autoantigenic sequences with bacterial-human sequence  matches Figure 6
Autoantigenic sequences with bacterial-human 
sequence matches. The frequency of proteins that contain 
a given number of bacterial-human exact sequence matches 
(min. 9 aa) is shown for autoantigens and non-autoantigenic 
SwissProt entries. Significantly more autoantigens have at 
least one bacterial-human exact sequence match than non-
autoantigenic human SwissProt entries. Furthermore, 
autoantigens also bear significantly more matches as com-
pared to non-autoantigenic ones (p < 0.05, Kolmogorov-
Smirnov).Immunome Research 2009, 5:4 http://www.immunome-research.com/content/5/1/4
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tage because of their glycan moiety when competing for
MHC binding, appears to be an interesting question with
practical consequences.
The fact that we found only a minimal proportion of
MHC II-restricted peptides to be glycosylated in case of
most MHC alleles, supports the notion that the glycan
moiety might indeed negatively affect glycopeptide pres-
entation. On the other hand, the relatively high propor-
tion of glycosylated peptides predicted to bind to certain
HLA alleles, might be an artifact caused by the highest sen-
sitivity, thus, a bit lower specificity of the prediction.
Higher permissivity of these alleles towards probable N-
but not O-glycosylation of peptides, however, might have
relevance to pathological immune responses, but this dif-
ference still needs to be experimentally confirmed.
T cell epitope glycosylation may also have implications to
autoimmunity. It may be hypothesized that within the
thymus, glycosylation of peptides interferes with their
presentation by protecting proteolytic cleavage sites. This
would be a mechanism parallel to that already reported in
case of O-glycosylation [3]. Not only the fact of glycosyla-
tion, but also the size and complexity of the N-glycan
moiety might play a significant role in the presentation of
N-glycosylated peptides [4]. In the absence of presenta-
tion, certain glycosylated parts of proteins may indeed,
escape thymic central tolerance induction. In the periph-
ery, however, glycosidase enzymes (of microbial or
inflammatory cell origin) may attack the glycan moieties,
and the naked peptides may become target neoepitopes of
an autoimmune recognition. In line with this concept, our
earlier data showed that elevated glycosidase activities
were indeed, predictors of rheumatoid arthritis [54]. Pro-
teins with higher number of N-glycosylation sites thus, are
more probably recognized by autoimmune T cells than
other proteins. In this work, we observed that the N-glyc-
osylation of autoantigens was significantly higher than
that of length-matched randomly generated sequences or
normal proteins.
Molecular mimicry has been shown in several human
autoimmune diseases [55] including multiple sclerosis
[56], Sydenham's chorea [57] rheumatic heart disease
[58], autoimmune thyroiditis [59], Chagas heart disease
[60], systemic lupus erythematosus, etc. [61]. Since over-
lapping human-bacterial sequences may trigger autoim-
mune processes, their immune recognition might be
substantial regarding autoimmunity. We found a reduced
glycosylation of the linear human-bacterial exact
sequence matches. As both T cell epitopes and bacterial-
human exact sequence matches are much shorter than full
length proteins, the reduced glycosylation observed in our
work, could have been attributed to the difference in pep-
tide length. Indeed, we found that glycosylation probabil-
ity increases in parallel with the peptide length. However,
we have shown in this study that the reduced glycosyla-
tion of neither the T cell epitopes, nor the human-bacte-
rial exact sequence matches were the function of peptide
length only.
According to most in vitro results, low glycosylation rates
of human T cell epitopes may be a prerequisite for an
effective immune recognition. Given the necessity of both
hypoglycosylation and the highest specificity for an
epitope sequence; the length of experimentally verified
human T cell epitopes occupies a niche optimized for
these two features (Figure 6). At the relevant peptide
lengths for MHC-II-restricted T cell epitopes, only a rela-
tively low number of bacterial-human exact sequence
matches can be found, and simultaneously the probabil-
ity of peptide glycosylation is also minimal.
Conclusion
There is a high need to improve the efficacy of T cell
epitope prediction [62]. Since currently available methods
ignore epitope glycosylation, taking it into account, might
yield in a more precise T cell epitope identification. Until
glycopeptides will be available on a large scale for cellular
immunology studies, this work may enable us to gain the
first system biology insight into the largely unknown role
of antigen glycosylation in T cell immunity. In spite of its
limitations, it may provide important clues for the design
of future experimental work.
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